LMR Partners LLP Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

LMR Partners LLP acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 64,817 shares of the company's stock, valued at approximately $1,429,000.

Several other hedge funds have also added to or reduced their stakes in the business. Integral Health Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $11,020,000. Iron Triangle Partners LP grew its holdings in shares of Teva Pharmaceutical Industries by 13.2% during the 4th quarter. Iron Triangle Partners LP now owns 2,200,036 shares of the company's stock worth $48,489,000 after purchasing an additional 256,246 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Teva Pharmaceutical Industries by 40.6% during the 4th quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company's stock worth $148,497,000 after purchasing an additional 1,945,688 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $332,000. Finally, Graham Capital Management L.P. grew its holdings in shares of Teva Pharmaceutical Industries by 148.4% during the 4th quarter. Graham Capital Management L.P. now owns 76,232 shares of the company's stock worth $1,680,000 after purchasing an additional 45,542 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $24.43.

Teva Pharmaceutical Industries Trading Up 0.5%

Shares of NYSE:TEVA traded up $0.08 during midday trading on Friday, reaching $16.95. The company's stock had a trading volume of 9,758,609 shares, compared to its average volume of 9,995,809. The firm has a market capitalization of $19.22 billion, a price-to-earnings ratio of -11.69, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50 day moving average price of $15.34 and a two-hundred day moving average price of $17.43. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the previous year, the firm posted $0.48 earnings per share. The business's revenue was up 1.9% compared to the same quarter last year. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.